Clinical characteristics of refractory myasthenia gravis patients

Joome Suh, Jonathan M Goldstein, Richard J Nowak, Joome Suh, Jonathan M Goldstein, Richard J Nowak

Abstract

Background: A subset of myasthenia gravis (MG) patients is refractory to standard therapies. Identifying the characteristics of this population is essential as newer treatment strategies emerge that may be more effective in this group.

Objective: The aim of our study is to describe the clinical features of refractory MG patients and compare them to those of non-refractory patients.

Methods: A retrospective chart review was completed of 128 MG patients referred to a tertiary neuromuscular clinic from 2003 to 2011. Patients were classified as refractory or non-refractory based on predefined criteria, and clinical features were compared.

Results: Nineteen out of 128 patients were classified as refractory (14.8 percent). Compared to the non-refractory patients, the refractory patients were more likely to be younger at onset, female, thymomatous, and MuSK-antibody positive.

Conclusion: Refractory MG patients represent a small but distinct group for whom exploring newer therapeutic approaches and immunopathologic differences is warranted.

Keywords: clinical features; myasthenia gravis; refractory disease.

Figures

Figure 1
Figure 1
Distribution of age of onset in refractory vs. non-refractory MG patients.

References

    1. Drachman DB. Myasthenia gravis. N Eng J Med. 1994;330(25):1797–1810.
    1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475–490.
    1. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843–2854.
    1. Silvestri NJ, Wolfe GI. Myasthenia gravis. Semin Neurol. 2012;32(3):215–226.
    1. Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve. 2010;41(3):375–378.
    1. Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord. 2011;4(5):259–266.
    1. Somnier FE, Keiding N, Paulson OB. Epidemiology of Myasthenia-Gravis in Denmark — a Longitudinal and Comprehensive Population Survey. Arch Neurol. 1991;48(7):733–739.
    1. Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S. et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann NY Acad Sci. 2008;1132:76–83.
    1. Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol. 2010;23(5):530–535.
    1. Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann NY Acad Sci. 2008;1132:305–314.
    1. Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol. 2009;16(2):246–250.
    1. Prakash KM, Ratnagopal P, Puvanendran K, Lo YL. Mycophenolate mofetil — as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience. J Clin Neurosci. 2007;14(3):278–281.
    1. Gladstone DE, Brannagan tH 3rd, Schwartzman RJ, Prestrud AA, Brodsky I. High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry. 2004;75(5):789–791.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren